Your browser doesn't support javascript.
loading
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S.
Jacob-Dolan, Catherine; Lifton, Michelle; Powers, Olivia C; Miller, Jessica; Hachmann, Nicole P; Vu, Mya; Surve, Nehalee; Mazurek, Camille R; Fisher, Jana L; Rodrigues, Stefanie; Patio, Robert C; Anand, Trisha; Le Gars, Mathieu; Sadoff, Jerald; Schmidt, Aaron G; Barouch, Dan H.
Afiliación
  • Jacob-Dolan C; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Lifton M; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA.
  • Powers OC; Harvard Medical School, Department of Microbiology, Boston, MA, USA.
  • Miller J; Harvard Medical School, Department of Immunology, Boston, MA, USA.
  • Hachmann NP; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Vu M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Surve N; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Mazurek CR; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Fisher JL; Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA, USA.
  • Rodrigues S; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Patio RC; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Anand T; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Le Gars M; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Sadoff J; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Schmidt AG; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Barouch DH; Janssen Vaccines and Prevention B.V., Leiden, the Netherlands.
iScience ; 27(5): 109716, 2024 May 17.
Article en En | MEDLINE | ID: mdl-38655202
ABSTRACT
The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time, even in the absence of boosting or infection. Here, we studied humoral responses following Ad26.COV2.S vaccination in individuals enrolled in the initial Phase 1/2a trial of Ad26.COV2.S in 2020. Through 8 months post vaccination, serum NAb responses increased to variants, including B.1.351 (Beta) and B.1.617.2 (Delta), without additional boosting or infection. The level of somatic hypermutation, measured by nucleotide changes in the VDJ region of the heavy and light antibody chains, increased in Spike-specific B cells. Highly mutated mAbs from these sequences neutralized more SARS-CoV-2 variants than less mutated comparators. These findings suggest that the increase in NAb breadth over time following Ad26.COV2.S vaccination is mediated by affinity maturation.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: IScience Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos